CERENOME INC
CNSYNASDAQπ #4743 by market capEarnings Oct 28US Equity
$1.74β² $0.06 (+3.88%)
Pre-market Β· at closeTrack CNSY
Get earnings, price moves & breaking news on Telegram
24hβ² 3.9%
7dβΌ 0.6%
14dβΌ 9.4%
30dβΌ 6.5%
ytdβΌ 86.4%
1yβΌ 87.1%
π¦Market Cap
$13M
Small Cap
πRevenue Growth (YoY)
-10.5%
Declining
πGross Margin
89.6%
High
π΅FCF Margin
-560.3%
Thin
βοΈP/S Ratio
3.1x
Fair
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $1.70 β $1.80
- 52-Week Range
- $1.49 β $19.00
- Volume (shares)
- 2,127
- Avg Volume (shares)
- β
- Shares Outstanding
- 7.6M
- Next Earnings
- 2026-10-28
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $411,000
- P/E Ratio
- -0.0
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-3.85
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1318622.0%
CERENOME INC
CNSYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5MβΌ β10.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.5%β² +7.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$15Mβ² +4.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$21Mβ² +94.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
3.1Mβ² +1318622.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mβ² +$11M YoY
About CERENOME INC
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.